menu
    • menu

    Find Anakinra manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    3

    API

    2

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    15

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    9

    Europe

    Europe

    1

    Canada

    Canada

    2

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    8DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    2

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    14

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    23,620,004

    Annual Reports

    1,099

    Finished Drug Prices

    Listed Dossiers

    16 RELATED EXCIPIENT COMPANIES

    33EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Interleukin1 receptor antagonist (human isoform x reduced),n2-l-methionyl- (9ci)
    Molecular Formula
    C20H23N5O7S2
    Molecular Weight
    509.6  g/mol
    InChI Key
    HMLGSIZOMSVISS-ONJSNURVSA-N
    Anakinra
    1 2D Structure

    Anakinra

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C20H23N5O7S2/c1-5-9-6-33-16-12(15(27)25(16)13(9)17(28)29)23-14(26)11(10-7-34-19(21)22-10)24-32-8-31-18(30)20(2,3)4/h5,7,12,16H,1,6,8H2,2-4H3,(H2,21,22)(H,23,26)(H,28,29)/b24-11-/t12-,16?/m1/s1
    2.1.3 InChI Key
    HMLGSIZOMSVISS-ONJSNURVSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C(=O)OCON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C=C)C(=O)O
    2.1.5 Isomeric SMILES
    CC(C)(C)C(=O)OCO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2C3N(C2=O)C(=C(CS3)C=C)C(=O)O
    2.2 Synonyms
    2.2.1 Depositor-Supplied Synonyms

    1. Interleukin1 Receptor Antagonist (human Isoform X Reduced),n2-l-methionyl- (9ci)

    2.3 Create Date
    2015-02-16
    3 Chemical and Physical Properties
    Molecular Weight 509.6 g/mol
    Molecular Formula C20H23N5O7S2
    XLogP31.1
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count10
    Exact Mass509.10389044 g/mol
    Monoisotopic Mass509.10389044 g/mol
    Topological Polar Surface Area227 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity961
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Kineret® Authorised For Emergency Use By Fda For The Treatment Of COVID-19 Related Pneumonia

    Details:

    Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.


    Lead Product(s): Anakinra

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Kineret

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 10, 2022

    blank

    01

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Kineret® Authorised For Emergency Use By Fda For The Treatment Of COVID-19 Related Pneumonia

    Details : Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.

    Brand Name : Kineret

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    November 10, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia

    Details:

    The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chances of full recovery.


    Lead Product(s): Anakinra

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2021

    blank

    02

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumo...

    Details : The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chance...

    Brand Name : Kineret

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    September 03, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sobi and Hellenic Institute for the Study of Sepsis: Anakinra Improved Overall Clinical Outcomes by 64% in Hospitalised Covid-19 Patients

    Details:

    In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.


    Lead Product(s): Anakinra

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Hellenic Institute for the Study of Sepsis

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 03, 2021

    blank

    03

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Hellenic Institute for the Study of Sepsis

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sobi and Hellenic Institute for the Study of Sepsis: Anakinra Improved Overall Clinical Outcomes b...

    Details : In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 inf...

    Brand Name : Kineret

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    May 03, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    NICE Issues Positive Recommendation for Use of Kineret to Treat Still’s Disease

    Details:

    NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).


    Lead Product(s): Anakinra

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Kineret

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 31, 2021

    blank

    04

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    NICE Issues Positive Recommendation for Use of Kineret to Treat Still’s Disease

    Details : NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (...

    Brand Name : Kineret

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    March 31, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    SOBI's Kineret® (anakinra) Approved in Russia for the Treatment of CAPS

    Details:

    Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.


    Lead Product(s): Anakinra

    Therapeutic Area: Genetic Disease Brand Name: Kineret

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 16, 2021

    blank

    05

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    SOBI's Kineret® (anakinra) Approved in Russia for the Treatment of CAPS

    Details : Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.

    Brand Name : Kineret

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    February 16, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Unique Clinical Trial Investigates a New Treatment Approach for Fatal ‘Childhood Alzheimer’s’ and Continues Despite COVID-19 Pandemic

    Details:

    The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.


    Lead Product(s): Anakinra

    Therapeutic Area: Genetic Disease Brand Name: Kineret

    Study Phase: Phase II/ Phase IIIProduct Type: Peptide

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 24, 2020

    blank

    06

    The Lundquist Institute

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    The Lundquist Institute

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Unique Clinical Trial Investigates a New Treatment Approach for Fatal ‘Childhood Alzheimer’sâ€...

    Details : The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.

    Brand Name : Kineret

    Molecule Type : Peptide

    Upfront Cash : Not Applicable

    June 24, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study

    Details:

    First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.


    Lead Product(s): Anakinra

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 08, 2020

    blank

    07

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study

    Details : First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    May 08, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sobi to Start a Clinical Study to Evaluate Whether Anakinra and Emapalumab May Relieve Complications Associated with Severe COVID-19 Disease

    Details:

    Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.


    Lead Product(s): Anakinra

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 18, 2020

    blank

    08

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anakinra

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sobi to Start a Clinical Study to Evaluate Whether Anakinra and Emapalumab May Relieve Complicatio...

    Details : Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    March 18, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Solubilizers

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    BASF

    Germany
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    05

    Actylis

    U.S.A
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Actylis

    U.S.A
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    07

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    08

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    09

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    10

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Parenteral

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Actylis

    U.S.A
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    05

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Actylis

    U.S.A
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    07

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    08

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Emulsifying Agents

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    05

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Topical

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    05

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Film Formers & Plasticizers

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Surfactant & Foaming Agents

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Thickeners and Stabilizers

    read-more
    read-more

    01

    Nanjing Well Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Brand Name : Polysorbate 80

    Application : Emulsifying Agents, Film Formers & Plasticizers, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical

    Excipient Details : Polysorbate 80 is used as a plasticizer, solubilizer, emulsifier, surfactant, and suspension stabilizer. It is also used in parenteral products.

    Pharmacopoeia Ref : ChP/USP/EP/JP

    Technical Specs : NA

    Ingredient(s) : Polysorbate 80

    arrow
    Polysorbate 80

    Excipients Web Link

    Market Place

    Digital Content

    Virtual Booth

    02

    Nanjing Bold Chemical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    03

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    04

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Co-Processed Excipients

    read-more
    read-more

    01

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    02

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Direct Compression

    read-more
    read-more

    01

    Seppic

    France
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    02

    Gangwal Chemicals

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Rheology Modifiers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    US Medicaid Prescriptions

    read-more
    read-more

    01

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 23,620,004

    Year : 2022

    Prescribers : 690

    Prescriptions : 4359

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 21,497,994

    Year : 2021

    Prescribers : 630

    Prescriptions : 4122

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 19,061,039

    Year : 2020

    Prescribers : 550

    Prescriptions : 3821

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 17,292,013

    Year : 2019

    Prescribers : 581

    Prescriptions : 3566

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 13,197,063

    Year : 2018

    Prescribers : 480

    Prescriptions : 2912

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 11,899,228

    Year : 2017

    Prescribers : 414

    Prescriptions : 2720

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 10,858,651

    Year : 2016

    Prescribers : 388

    Prescriptions : 2455

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    Anakinra

    Drug Cost (USD) : 8,767,048

    Year : 2015

    Prescribers : 398

    Prescriptions : 2335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : KINERET

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : KINERET

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company :

    ANAKINRA

    Drug Cost (USD) : 8,004,714

    Year : 2014

    Prescribers : 394

    Prescriptions : 2234

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Finished Drug Prices

    read-more
    read-more

    01

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    SWEDISH ORPHAN BIOVITRUM AB(PU

    Anakinra

    Dosage Form : Anakinra 100Mg 0.67 Ml 7 Joined ...

    Dosage Strength : 7 Syringes SC 100 mg 0,67 ml

    Price Per Pack (Euro) : 328.96

    Published in :

    Country : Italy

    RX/OTC/DISCN : Class H

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    SWEDISH ORPHAN BIOVITRUM AB(PU

    Anakinra

    Dosage Form : Anakinra 100Mg 0.67 Ml 7 Joined ...

    Dosage Strength : 7 Syringes SC 100 mg 0,67 ml

    Price Per Pack (Euro) : 328.96

    Published in :

    Country : Italy

    RX/OTC/DISCN : Class H

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biovitrum AB (publ)

    Anakinra

    Dosage Form : Injection fluid, resolution

    Dosage Strength : 100 mg/0.67 ml

    Price Per Pack (Euro) : 259.26

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biovitrum AB (publ)

    Anakinra

    Dosage Form : Injection fluid, resolution

    Dosage Strength : 100 mg/0.67 ml

    Price Per Pack (Euro) : 1,022.81

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Biovitrum AB (publ)

    Anakinra

    Dosage Form : Injection fluid, resolution

    Dosage Strength : 100 mg/0.67 ml

    Price Per Pack (Euro) : 1,022.81

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Kineret

    Denmark
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Denmark
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Orifarm AS

    Anakinra

    Dosage Form : Injection fluid, resolution

    Dosage Strength : 100 mg/0.67 ml

    Price Per Pack (Euro) : 1,022.81

    Published in :

    Country : Norway

    RX/OTC/DISCN :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Annual Reports

    read-more
    read-more

    01

    Brand Name : Kineret

    Anakinra

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Anakinra

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 157

    2018 Revenue in Millions : 132

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kineret

    Anakinra

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Anakinra

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 249

    2019 Revenue in Millions : 188

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kineret

    Anakinra

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Anakinra

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 246

    2020 Revenue in Millions : 229

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kineret

    Anakinra

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Anakinra

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 215

    2021 Revenue in Millions : 246

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kineret

    Anakinra

    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Brand Name : Kineret

    Sweden
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Swedish Orphan Biovitrum AB

    Anakinra

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 232

    2022 Revenue in Millions : 215

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    Health Canada Patents

    read-more
    read-more

    01

    Med-Script Associates Ltd.

    Anakinra
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Med-Script Associates Ltd.

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2013-09-17

    Date Granted : 2008-04-08

    Anakinra

    Brand Name : KINERET

    Patent Number : 2141953

    Filing Date : 1993-09-17

    Strength per Unit : 100 mg / 0.67 mL

    Dosage Form : Injectable Solution

    Human Or VET : Human

    Route of Administration : Subcutaneous

    Patent Expiration Date : 2013-09-17

    Date Granted : 2008-04-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Med-Script Associates Ltd.

    Anakinra
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Med-Script Associates Ltd.

    Country
    arrow
    Medlab Asia & Asia Health
    Not Confirmed

    Patent Expiration Date : 2018-11-27

    Date Granted : 2001-11-27

    Anakinra

    Brand Name : KINERET

    Patent Number : 1341322

    Filing Date : 1989-05-26

    Strength per Unit : 100 mg / 0.67 mL

    Dosage Form : Injectable Solution

    Human Or VET : Human

    Route of Administration : Subcutaneous

    Patent Expiration Date : 2018-11-27

    Date Granted : 2001-11-27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search